Jennison Associates Portfolio holdings
Jennison Associates is the research-driven stock investing arm of PGIM, the asset management business of Prudential Financial. It started in 1969, through a predecessor company, managing growth stock accounts of large U.S. companies, mainly for large institutions, and Prudential bought it in 1985. Its growth stock investors believe that rising earnings and cash flow drive share prices, and it also runs long-only and long/short portfolios of global healthcare companies. It began advising mutual funds in 1990 and also manages bond portfolios, choosing investments through its own company-by-company research. Its clients include pension plans, public employee retirement systems, foundations and endowments.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$1.27B |
| 2 |
Sandisk
SNDK
|
+$674M |
| 3 |
Credo Technology Group
CRDO
|
+$476M |
| 4 |
Nebius Group N.V.
NBIS
|
+$452M |
| 5 |
Vertiv
VRT
|
+$420M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.98B |
| 2 |
Amazon
AMZN
|
+$1.25B |
| 3 |
Shopify
SHOP
|
+$1.08B |
| 4 |
Edwards Lifesciences
EW
|
+$1.07B |
| 5 |
Microsoft
MSFT
|
+$630M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.11% |
| 2 | Communication Services | 13.94% |
| 3 | Consumer Discretionary | 10.64% |
| 4 | Industrials | 9.08% |
| 5 | Healthcare | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
TeraWulf
WULF
$6.54B
| $110M | 0.07% |
4,469,069
+767,174
| +21% | +$17.6M |
2026 Q1
1 quarter
|
|
152
IBM
IBM
$231B
| $110M | 0.07% |
389,932
-246,326
| -39% | -$62.1M |
2022 Q2
16 quarters
|
|
153
Quanta Services
PWR
$91.3B
| $109M | 0.07% |
152,041
+25,341
| +20% | +$17.3M |
2014 Q3
47 quarters
|
|
154
Acadian Asset Management
AAMI
$3.36B
| $109M | 0.07% |
1,526,570
-495,637
| -25% | -$34.5M |
2017 Q2
36 quarters
|
|
155
Urban Edge Properties
UE
$2.66B
| $109M | 0.07% |
4,757,938
+172,682
| +4% | +$3.81M |
2023 Q4
10 quarters
|
|
156
Elbit Systems
ESLT
$33.9B
| $109M | 0.07% |
143,473
-7,436
| -5% | -$6.18M |
2026 Q1
1 quarter
|
|
157
Semtech
SMTC
$11.1B
| $108M | 0.06% |
667,291
-77,089
| -10% | -$10.1M |
2025 Q3
3 quarters
|
|
158
Intel
INTC
$325B
| $108M | 0.06% |
+772,639
| New | +$78.1M |
2026 Q2
0 quarters
|
|
159
TechnipFMC
FTI
$25.2B
| $106M | 0.06% |
1,599,692
+11,168
| +0.7% | +$791K |
2022 Q3
15 quarters
|
|
160
Heritage Financial
HFWA
$1.14B
| $105M | 0.06% |
3,538,159
+324,686
| +10% | +$8.93M |
2024 Q1
9 quarters
|
|
161
Tarsus Pharmaceuticals
TARS
$3.79B
| $105M | 0.06% |
1,663,655
-48,469
| -3% | -$3.1M |
2024 Q1
9 quarters
|
|
162
MACOM Technology Solutions
MTSI
$18.8B
| $103M | 0.06% |
269,632
-30,093
| -10% | -$10M |
2020 Q4
22 quarters
|
|
163
Stryker
SYK
$119B
| $102M | 0.06% |
+323,435
| New | +$102M |
2026 Q2
0 quarters
|
|
164
Generac Holdings
GNRC
$11.4B
| $102M | 0.06% |
347,460
-173,168
| -33% | -$43.4M |
2024 Q3
7 quarters
|
|
165
Regal Rexnord
RRX
$12B
| $101M | 0.06% |
422,076
+58,958
| +16% | +$12.3M |
2021 Q4
18 quarters
|
|
166
Burlington
BURL
$15.8B
| $100M | 0.06% |
316,336
-10,264
| -3% | -$3.31M |
2015 Q1
45 quarters
|
|
167
Dianthus Therapeutics
DNTH
$5.21B
| $100M | 0.06% |
1,021,763
+536,627
| +111% | +$46.9M |
2026 Q1
1 quarter
|
|
168
CVS Health
CVS
$115B
| $97.5M | 0.06% |
942,869
+14,816
| +2% | +$1.32M |
2024 Q4
6 quarters
|
|
169
Bel Fuse Inc Class B
BELFB
$3.37B
| $97.3M | 0.06% |
+292,065
| New | +$78.9M |
2026 Q2
0 quarters
|
|
170
Concentra Group Holdings
CON
$5.4B
| $96.9M | 0.06% |
3,256,435
+1,084,144
| +50% | +$27M |
2025 Q3
3 quarters
|
|
171
Insmed
INSM
$25.9B
| $96.5M | 0.06% |
905,094
+300,400
| +50% | +$36.4M |
2023 Q4
10 quarters
|
|
172
Corning
GLW
$103B
| $95.1M | 0.06% |
372,407
+39,135
| +12% | +$7.12M |
2020 Q4
22 quarters
|
|
173
Flywire
FLYW
$2.67B
| $92.6M | 0.06% |
5,272,962
-25,919
| -0.5% | -$383K |
2022 Q2
16 quarters
|
|
174
Permian Resources
PR
$19.1B
| $92.5M | 0.06% |
5,025,209
-1,204,825
| -19% | -$24.2M |
2023 Q3
11 quarters
|
|
175
Veradermics Inc
MANE
$5.71B
| $92M | 0.06% |
748,678
+606,897
| +428% | +$56.9M |
2026 Q1
1 quarter
|
|
Similar funds
Jennison Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Jennison Associates held 641 positions worth $167B, up 15% from $145B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Jennison Associates withdrew a net $6.22B in Q2 2026, closing 74 positions and reducing 282 holdings. Its most notable exit was Gilead Sciences, an estimated $176M position sold in full.
By sector, the portfolio is most concentrated in Technology at 43% of assets, up from 39% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, Jennison Associates opened a new position in SpaceX worth $1.27B.
- Jennison Associates's largest Q2 2026 buy was SpaceX: 7,448,891 shares worth $1.27B.
- Jennison Associates added most to Credo Technology Group in Q2 2026, an estimated $476M increase.
- Jennison Associates's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.98B.
- Jennison Associates fully exited Gilead Sciences in Q2 2026, selling an estimated $176M.
- Jennison Associates's ten largest holdings make up 45% of its $167B portfolio in Q2 2026.
- Jennison Associates opened 79 new positions and closed 74 in Q2 2026.
- Jennison Associates's portfolio value rose 15% quarter-over-quarter to $167B.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.